HESS-STUMP HOLGER
No ORCID on file
· 90 papers in corpus
· active 2001-2007
Frequent coauthors
- ZORN LUDWIG 60
- HUTH ANDREAS 60
- KRUEGER MARTIN 60
- MENRAD Andreas 60
- THIERAUCH Karl-Heinz 60
- HABEREY Martin 60
- INCE STUART 60
- HAENDLER Bernard 30
- CHWALISZ Kristof 30
- LESSEY Bruce 30
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …